Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25016257 | 0.95 | F10 (0.45) | F10PRSS1F2PTGS2PTGS1 | |
| SCHEMBL25016300 | 0.91 | F10 (0.43) | F10PRSS1F2PTGS2CCNC | |
| SCHEMBL25017873 | 0.88 | CCR2 (0.43) | F10PRSS1F2 | |
| SCHEMBL25016258 | 0.88 | F10 (0.44) | F10PRSS1F2PTGS2CCNC | |
| SCHEMBL21822321 | 0.87 | F10 (0.42) | F10PRSS1F2ITGB3ITGA2B | |
| SCHEMBL25015733 | 0.86 | F10 (0.42) | F10PRSS1F2PTGS2ITGB3 | |
| SCHEMBL25017370 | 0.86 | F10 (0.51) | F10PRSS1F2PTGS2PRSS2 | |
| SCHEMBL25017397 | 0.85 | ITGB3 (0.44) | F10PRSS1F2ITGB3ITGA2B | |
| SCHEMBL25016280 | 0.85 | F10 (0.46) | F10PRSS1F2ITGB3ITGA2B | |
| SCHEMBL25017891 | 0.85 | F10 (0.44) | F10PRSS1F2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | F10 1548/4885PRSS1 39/4885F2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.